1. Introduction {#s1}
===============

Heart failure (HF) is one of the most burgeoning healthcare problems in Cardiology Department. It causes considerable morbidity and mortality, the frequency of hospitalization for HF has been increasing in recent years. In several published registries, in-hospital mortality of HF patients ranges from 4% to 7%.[@b1]--[@b3] Most patients with HF are elderly, constituting up to 80% of patients suffering from this disease, both the incidence and prevalence of HF increase with age.[@b4] In patients with HF, age is associated with an increased risk of cardiovascular events and mortality during short- and long- term follow-up.[@b5],[@b6]

Clinical risk prediction tools may be helpful in guiding medical decision making and improving prognosis. Previous studies generally based on outpatients with chronic heart failure (CHF), have identified a number of variables that are associated with increased mortality. Patients with CHF may readmit for acute heart failure (AHF). During hospital admissions for AHF, the majority of patients\' symptoms are relieved. However, not all patients recover well. Despite standard initial therapy, some subsets of patients experience worsening heart failure (WHF) or even death that is inevitable during hospitalization.

Early identification of risk factors that accelerate in-hospital mortality may improve prognosis and aid in decision making. Although there are several in-hospital mortality prediction models available, data on such prediction models in elderly patients is limited. For example, the American Heart Association get with the guidelines--heart failure (GWTG-HF) program risk score was established based on a large sample size, however, it was not validated in a separate population (e.g. elderly patients). Acute physiology and chronic health evaluation (APACHE II) is another scoring system that is used to assess the severity of the disease. However, it contains too many parameters to make it easy to use. Although age is an independent risk factor in patients with HF,[@b7] there are few studies on risk prediction models for elderly patients. Therefore, the objective of the present study was to develop a risk stratification practice method for in-hospital mortality among elderly patients who were admitted with AHF; this method is applicable in routine clinical practice.

2. Methods {#s2}
==========

2.1. Patient population and study design {#s2a}
----------------------------------------

This retrospective study was performed in intensive care units of the Cardiology Department in the Chinese PLA General Hospital. For the purpose of our study, diagnosis of AHF was made according to the inclusion criteria from the European Society of Cardiology according to symptoms or signs, electrocardiogram, chest radiograph, and echocardiography.[@b8] Patients were identiﬁed for inclusion in the study from admission when given a diagnosis of AHF based on International Classification of Diseases, Ninth/Tenth Revision (ICD-9/10) coding from 2003 January to 2016 October (*n* = 3026 ). The exclusion criteria included the following: younger than 60 years old (*n* = 295), malignant tumors (*n* = 23), acute coronary syndrome (*n* = 174), acute cerebrovascular diseases within the past three months (*n* = 37), immunological diseases (*n* = 11) and other patients in any case that were not suitable for this study.

According to the criteria mentioned above, 2486 patients who were 60 years and older with AHF in intensive care units of the Chinese PLA General Hospital were screened, and 55 patients were excluded for missing data. The study population was randomly divided into derivation (70%, *n* = 1702) and validation (30%, *n* = 729) groups.[@b9] AHF patients were grouped according to the outcomes. Flow chart of study participants was shown in [Figure 1](#jgc-14-11-669-g001){ref-type="fig"}. Patients\' demographic and baseline characteristics, past medical history, clinical presentation, treatments, laboratory tests, and outcomes during admission were recorded. The study was approved by the Ethical Committee for Medical Research of Chinese PLA General Hospital.

![Flow chart of study participants (*n* = 2431).\
AHF: acute heart failure; ICD: international classiﬁcation of diseases.](jgc-14-11-669-g001){#jgc-14-11-669-g001}

2.2. Statistical analysis {#s2b}
-------------------------

All statistical operations in this study were completed by the Department of Statistics of Peking University Health Science Center. The normal distribution test for continuous variables was conducted using the Kolmogorov-Smirnov test. Continuous variables were presented as the mean ± SD or median (25^th^--75^th^ percentiles) according to normality. Statistical analysis of normal distribution data was performed using an unpaired Student\'s *t*-test between two groups. Non-normal distribution data were analyzed using the Mann-Whitney U test for continuous variables and the *χ*^2^ test for discrete variables. Multivariate analysis was conducted using binary logistic regression. Statistical results are expressed as odds ratios (OR) and 95% confidence intervals (CI). We used the forward method to exclude insignificant variables. The receiver operator characteristic curve (ROC) of significant variables and C-statistic testing were utilized to assess the performance of the constructed model in comparison with a previously published model. All tests were carried out using SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) and MedCalc version 15.6.1 (MedCalc Software, Mariakerke, Belgium) statistical software. Differences were considered statistically signiﬁcant at a two-tailed *P* value of less than 0.05.

3. Results {#s3}
==========

In total, 2431 patients with AHF were included in this retrospective study. Based on the grouping method of a previous study, 2431 patients were randomly divided into derivation (70%, *n* = 1702) and validation (30%, *n* = 729) groups.[@b9]

The baseline characteristics, physiological parameters and management of patients in the derivation group are shown in [Table 1](#jgc-14-11-669-t01){ref-type="table"}. A total of 1702 patients were included. They were divided into two groups according to their outcomes during hospitalization. In total, 90 patients who died and 1612 who survived during hospitalization were included. The two groups were similar with respect to age, sex distribution, systolic blood pressure, diastolic blood pressure and body mass index. In the past medical history, patients dying during hospital stay had a great number of pulmonary infection (57.77% *vs*. 37.47%, *P* \< 0.001) compared with patients surviving during hospitalization. Serum creatinine, blood[@b9] urea nitrogen (BUN) and NT-pro BNP were much higher in the deceased group while the pH value and standard HCO~3~ were significantly decreased. The echocardiographic results showed that left ventricular ejection fraction (LVEF) and fractional shortening (FS) were decreased in patients dying during hospital stay, indicating changes in left ventricular function. Regarding management and drug treatment, patients dying during hospital stay received more asthma drugs, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), morphine and vasoactive drugs during hospitalization.

###### Characteristics of patients in derivation group.

                             Patients dying during Hospital stay (*n* = 90)   Patients surviving during Hospital stay (*n* = 1612)   *P*-value
  ------------------------- ------------------------------------------------ ------------------------------------------------------ -----------
  Age                                         75.35 ± 6.73                                        72.27 ± 7.82                         0.168
  Male                                        47 (52.22%)                                         813 (50.43%)                         0.167
  Medical history                                                                                                                   
   Coronary Heart Disease                     46 (51.11%)                                         825 (51.19%)                         0.990
   Cardiomyopathy                              8 (8.89%)                                           79 (4.80%)                          0.154
   Hypertension                               47 (52.22%)                                         913 (56.64%)                         0.411
   Pulmonary infection                        52 (57.77%)                                         604 (37.47%)                       \< 0.001
   Valvular Heart disease                     13 (14.44%)                                         204 (12.66%)                         0.620
   Pulmonary hypertension                      7 (7.78%)                                          111 (6.89%)                          0.746
   Diabetes                                   31 (34.44%)                                         558 (34.62%)                         0.974
   Chronic kidney disease                     30 (33.33%)                                         419 (25.99%)                         0.124
   Arrhythmia                                 22 (24.44%)                                         486 (30.15%)                         0.250
   Hyperlipidemia                              7 (7.78%)                                          205 (12.72%)                         0.167
  Physical examination                                                                                                              
   HR, beats/min                         92.00 (79.00--108.00)                                81.00 (73.00--96.00)                     0.027
   RR, breaths/min                        21.00 (16.00--23.00)                                18.00 (17.00--20.00)                     0.002
   SBP, mmHg                                 131.00 ± 26.00                                      127.00 ± 23.00                        0.635
   DBP, mmHg                                 78.00 ± 17.00                                       74.00 ± 15.00                         0.752
   BMI, kg/m^2^                               23.70 ± 6.63                                        24.75 ± 7.93                         0.367
  Biochemical                                                                                                                       
   ALT, U/L                               24.50 (13.80--37.90)                                17.50 (11.80--22.80)                     0.073
   AST, U/L                               29.50 (19.20--54.60)                                22.50 (16.33--28.69)                     0.038
   γ-GT, U/L                              40.30 (24.80--71.00)                                31.70 (21.83--68.30)                     0.255
   Cr, umol/L                            132.80 (90.70--246.00)                              84.20 (65.83--125.80)                   \< 0.001
   BUN, mmol/L                            12.33 (7.29--18.58)                                  7.28 (5.20--10.29)                      0.015
   Uric acid, umol/L                    380.60 (281.00--476.80)                             365.35 (294.80--461.73)                    0.735
   TG, mmol/L                              1.13 (0.86--1.72)                                   1.24 (0.88--1.85)                       0.192
   T-CH, mmol/L                            3.82 (3.25--4.60)                                   3.86 (3.19--4.65)                       0.220
   HDL, mmol/L                             0.95 (0.73--1.22)                                   1.00 (0.80--1.28)                       0.964
   LDL, mmol/L                             2.25 (1.61--2.84)                                   2.31 (1.81--2.85)                       0.334
   CK, U/L                                73.60 (42.10--162.1)                               77.60 (39.85--164.25)                     0.866
   c-TnT. ng/L                             0.04 (0.01--0.16)                                   0.05 (0.02--0.19)                       0.941
   NT-pro BNP, pg/ml                  12171.21 (2585.08--20885.10)                         3537.39 (1140.15--6904.50)                  0.019
   Hemoglobin, g/L                      124.00 (100.00--135.00)                              120.00 (99.00--136.00)                    0.738
   RBC, 10^12^/L                           4.19 (3.43--4.65)                                   4.00 (3.39--4.45)                       0.436
   WBC, 10^9^/L                            7.26 (5.62--10.03)                                  7.64 (5.91--9.28)                       0.788
   PLT, 10^9^/L                         186.00 (140.00--244.00)                             186.50 (135.25--238.00)                    0.621
  ABG                                                                                                                               
   pH value                                7.35 (7.32--7.42)                                   7.39 (7.38--7.44)                     \< 0.001
   PaO~2~, mmHg                           84.27 (60.00--99.60)                                80.21 (61.60--90.28)                     0.316
   PaCO~2~, mmHg                          37.42 (32.03--41.48)                                37.72 (32.03--41.48)                     0.388
   HCO~3~, mmol/L                         21.02 (18.00--23.60)                                22.50 (19.80--24.90)                     0.001
   SaO~2~, %                              92.47 (91.10--97.90)                                93.72 (92.58--97.40)                     0.303
  Echocardiographic                                                                                                                 
   LVDD, mm                               52.64 (46.00--59.00)                                50.69 (45.00--57.00)                     0.050
   LVSD, mm                               40.83 (33.00--48.00)                                37.96 (31.00--44.00)                   \< 0.001
   LVEF, %                                38.84 (30.00--45.00)                                48.66 (38.00--58.00)                   \< 0.001
   FS, %                                  20.37 (16.00--23.00)                                25.48 (20.00--30.00)                   \< 0.001

Data were presented as mean ± SD, *n* (%) or median (25th--75th percentiles). ABG: arterial blood gas; ALT: alanine transferase; AST: aspartate aminotransferase; BUN: blood urea nitrogen; BMI: body mass index; CK: creatine kinase; c-TnT: cardiac troponin T; Cr: creatinine; DBP: diastolic blood pressure; FS: fractional shortening; HR: heart rate; HDL: high density lipoprotein; LDL: low density lipoprotein; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic dysfunction; LVEF: left ventricular ejection fraction; NT-pro BNP: PLT: platelets; PH: potential of hydrogen; PaO~2~: partial pressure of O~2~; PaCO~2~: partial pressure of CO~2~; RR: respiratory rate; RBC: red blood count; SBP: systolic blood pressure; TG: triglyceride; T-CH: total cholesterol; WBC: white blood count; γ-GT: γ-glutamyl transpeptidase.

According to the results presented in [Table 1](#jgc-14-11-669-t01){ref-type="table"}, heart rate (HR), respiratory rate (RR), aspartate aminotransferase (AST), eGFR (calculated by MDRD method), NT-pro BNP, pH value, HCO~3~^−^, left ventricular diastolic diameter (LVDD), left ventricular systolic diameter (LVSD), LVEF, FS and past history of cardiomyopathy, pulmonary infection, and chronic kidney disease were entered into a multivariable logistic regression model. The signiﬁcant variables included HR (OR: 1.043, 95% CI: 1.030--1.057, *P* \< 0.001), LVEF (OR: 0.918, 95% CI: 0.873--0.966, *P* = 0.001), pH value (OR: 0.001, 95% CI: 0.000--0.002, *P* \< 0.001), eGFR (OR: 0.120, 95% CI: 0.066--0.220, *P* \< 0.001), and NT-pro BNP (OR: 3.463, 95% CI: 1.870--6.413, *P* \< 0.001) ([Table 3](#jgc-14-11-669-t03){ref-type="table"}).

###### Binary logistic regression model.

  Factors                     B       SE      Wals    df   *P* value    OR     95% CI  
  ------------------------ -------- ------- -------- ---- ----------- ------- -------- -------
  HR, beats/min             0.042    0.007   40.050   1      0.000     1.043   1.030    1.057
  LVEF, %                   −0.085   0.026   11.000   1      0.001     0.918   0.873    0.966
  pH value                  −6.028   4.737   11.450   1      0.001     0.001   0.000    0.002
  eGFR, mL/min/1.73 m^2^    −2.118   0.308   47.326   1      0.000     0.120   0.066    0.220
  NT-pro BNP, pg/mL         1.242    0.314   15.608   1      0.000     3.463   1.870    6.413

CI: conﬁdence interval; eGFR: estimated glomerular filtration rate; HR: heart rate; LVEF: left ventricular ejection fraction; NT-pro BNP: N-terminal pro-b-type natriuretic peptide; OR: odds ratios; SE: standard error.

###### Areas under the ROC curve for the following ﬁve variables: HR, LVEF, pH value, eGFR and NT-pro BNP.

  Factors                   Area     SE     *P* value   95% CI   Youden\'s index  
  ------------------------ ------- ------- ----------- -------- ----------------- -------
  HR, beats/min             0.733   0.022     0.000     0.736         0.822        0.361
  LVEF, %                   0.723   0.022     0.000     0.678         0.765        0.393
  pH value                  0.681   0.026     0.000     0.628         0.731        0.385
  eGFR, mL/min/1.73 m^2^    0.773   0.022     0.000     0.737         0.807        0.471
  NT-pro BNP, pg/mL         0.720   0.025     0.000     0.672         0.769        0.409

CI: conﬁdence interval; eGFR: estimated glomerular filtration rate; HR: heart rate; LVEF: left ventricular ejection fraction; NT-pro BNP: N-terminal pro-b-type natriuretic peptide; OR: odds ratios; ROC: receiver operator characteristic; SE: standard error.

All patients were stratiﬁed according to quartiles of HR (Q1, 43.00 to 75.00; Q2, 76.00 to 83.00; Q3, 84.00 to 103.00; and Q4,104.00 to 166.00), pH value (Q1, 6.785 to 7.366; Q2, 7.367 to 7.400; Q3, 7.401 to 7.435; and Q4, 7.436 to 7.524), eGFR (Q1, 24.40 to 33.47; Q2, 33.48 to 63.07; Q3, 63.08 to 86.65; and Q4, 86.66 to 120.24) and NT-pro BNP (Q1, 950.5 to 2257.5; Q2, 2257.6 to 5737.5; Q3, 5737.6 to 9369.5; and Q4, 9369.6 to 3,5000). The clinical outcomes of each quartile group are shown in [Figure 2. (A--E)](#jgc-14-11-669-g002){ref-type="fig"}. The incidence of patients in the deceased group for Q1 was higher than the other three groups according to the pH value and eGFR, while the incidence of the deceased group in Q1 was the lowest according to HR and NT-pro BNP. Furthermore, the incidence of patients dying during hospitalization with reduced LVEF was higher than that of patients with preserved LVEF. Acid-base imbalance often occurs in HF patients, and the pH value is an excellent warning indicator of adverse cardiac events. [Figure 3. (A--C)](#jgc-14-11-669-g003){ref-type="fig"} shows the distribution of the pH values for all patients.

![Clinical outcomes of each index in quartile group.\
(A): clinical outcomes of each HR quartile group; (B): clinical outcomes of each pH value quartile group; (C): clinical outcomes according to EF; (D): clinical outcomes of each eGFR quartile group; (E): clinical outcomes of each NT-pro BNP quartile group. eGFR: epidermal growth factor rate; EF: ejection fraction; NT-pro BNP: N-terminal pro-b-type natriuretic peptide.](jgc-14-11-669-g002){#jgc-14-11-669-g002}

![Clinical outcomes according to pH value.\
(A): the distribution of pH value in all patients; (B): the distribution of pH value in patients Survived during hospital; (C): the distribution of pH value in patients Died during hospital.](jgc-14-11-669-g003){#jgc-14-11-669-g003}

Using the various indicators of the ROC curve ([Figure 4](#jgc-14-11-669-g004){ref-type="fig"}), we calculated Youden\'s index to determine the cutoff value of each index ([Table 3](#jgc-14-11-669-t03){ref-type="table"}). We established a risk prediction model of adverse cardiac events and obtain the probability of adverse cardiac events according to different values of the independent variable as shown in [Table 3](#jgc-14-11-669-t03){ref-type="table"}. We established the following in-hospital mortality prediction algorithm (PA): logit (*P*) = 78.023 + 0.042 × HR -- 0.085 × LVEF -- 6.028 × pH -- 2.118 × eGFR + 1.242 × NT pro-BNP. The closer the *P* value is to 1, the greater the likelihood of adverse cardiac events. To facilitate clinical practice, we used the five independent risk factors selected by binary logistic regression to establish a Risk Prediction Score System (RPSS).[@b10],[@b11] According to the OR value of the independent risk factors screened by logistic regression for in-hospital mortality, the risk factors were assigned, the non-integral OR values were taken from four to five, and the corresponding risk integral values of risk factors were obtained ([Table 4](#jgc-14-11-669-t04){ref-type="table"}).

![ROC curves for the signiﬁcant variables.\
eGFR: estimated glomerular filtration rate; GWTG-HF: get with the guidelines--heart failure; HR: heart rate; LVEF: left ventricular ejection fraction; NT-pro BNP: N-terminal pro-b-type natriuretic peptide; PA: prediction algorithm; ROC: receiver operating characteristic; RPSS: risk prediction score system.](jgc-14-11-669-g004){#jgc-14-11-669-g004}

###### Scoring system of the prediction risk model.

    Factors      Range    Score
  ------------ --------- -------
      eGFR       ≤ 33       3
     33--60        2     
     60--90        1     
     \> 90         0     
       HR        ≤ 75       0
    75--100        1     
     \> 100        2     
      LVEF       ≤ 45       0
     \> 45         1     
   NT-pro BNP    ≤ 200      0
   200--3500       1     
   3500--8440      2     
    \> 8440        3     
    pH value    ≤ 7.362     1
    \> 7.362       0     

EGFR: estimated glomerular filtration rate; HR: heart rate; LVEF: left ventricular ejection fraction; NT-pro BNP: N-terminal pro-b-type natriuretic peptide.

The GWTG-HF risk score uses routinely collected clinical data to predict the risk of in-hospital mortality for patients hospitalized with HF. Age, systolic blood pressure, and BUN are the admission variables that are most predictive of in-hospital mortality; admission heart rate, serum sodium, chronic obstructive pulmonary disease (COPD) presence, and nonblack race contribute modestly. We calculated the GWTG-HF score for all patients. To assess the prediction effectiveness of PA and RPSS, we compared the ROC curves of the three methods. The area under the ROC curve values for RPSS, PA and GWTG-HF were 0.873, 0.829, and 0.818, respectively ([Figure 5](#jgc-14-11-669-g005){ref-type="fig"}). The cut-off of the ROC curve for RPSS is four points. Therefore, clinical doctors should focus special attention on patients with more than four points.

![Pairwise comparison of ROC curves for GWTG-HF, PA and PSS.\
GWTG-HF: get with the guidelines--heart failure; PA: prediction algorithm; ROC: receiver operating characteristic; RPSS: risk prediction score system.](jgc-14-11-669-g005){#jgc-14-11-669-g005}

Furthermore, we compared the characteristics of the derivation group and validation group. The baseline characteristics, physiological parameters, management, biochemical test, blood-gas-analysis and echocardiographic results of all subjects are shown in [Table 5](#jgc-14-11-669-t05){ref-type="table"}. There is no significant difference between the two groups. The area under the ROC curve values for the validation RPSS is 0.863 ([Figure 6](#jgc-14-11-669-g006){ref-type="fig"}). The cut-off of the ROC curve for the validation group is also four points.

###### Characters of the derivation group and validation group.

                             Derivation group (*n* = 1702)   Validation group (*n* = 729)   *P*-value
  ------------------------- ------------------------------- ------------------------------ -----------
  Age                                73.52 ± 6.57                    74.72 ± 5.12             0.842
  Male                               860 (50.53%)                    401 (55.00%)             0.467
  Medical history                                                                          
   Coronary Heart Disease            871 (51.18%)                    379 (51.99%)             0.713
   Cardiomyopathy                     87 (5.11%)                      65 (8.92%)            \< 0.001
   Hypertension                      960 (56.04%)                    399 (54.73%)             0.447
   Pulmonary infection               656 (38.54%)                    291 (39.92%)             0.524
   Valvular Heart disease            217 (12.75%)                    74 (10.15%)              0.071
   Pulmonary hypertension             118 (6.93%)                     60 (8.23%)              0.261
   Diabetes                          589 (34.61%)                    233 (31.96%)             0.207
   Chronic kidney disease            449 (25.50%)                    203 (27.86%)             0.455
   Arrhythmia                        508 (29.85%)                    197 (27.02%)             0.160
   Hyperlipidemia                    212 (12.46%)                    87 (11.93%)              0.720
  Physical examination                                                                     
   HR, beats/min                 84.00 (73.00--99.00)            82.00 (72.00--94.00)         0.121
   RR, breaths/min               18.00 (17.00--20.00)            18.00 (18.00--20.00)         0.874
   SBP, mmHg                        127.00 ± 28.00                  129.50 ± 23.25            0.737
   DBP, mmHg                         74.00 ± 16.00                  77.50 ± 15.00             0.539
   BMI, kg/m^2^                      24.66 ± 7.23                    24.60 ± 9.27             0.886
  Biochemical                                                                              
   ALT, U/L                      19.50 (11.80--35.80)            17.90 (14.20--33.25)         0.361
   AST, U/L                      28.50 (16.23--33.69)            26.38 (16.10--34.72)         0.736
   γ-GT, U/L                     36.70 (22.83--68.38)            32.60 (20.88--74.17)         0.835
   Cr, umol/L                   103.20 (75.83--145.80)          97.00 (68.90--149.95)         0.800
   BUN, mmol/L                    7.37 (5.20--15.33)              7.71 (5.67--12.94)          0.373
   Uric acid, umol/L            365.65 (294.80--461.84)        353.35 (291.50--475.73)        0.395
   TG, mmol/L                      1.34 (0.88--2.11)              1.49 (0.99--3.17)           0.218
   T-CH, mmol/L                    3.86 (3.09--4.04)              3.86 (3.82--5.88)           0.756
   HDL, mmol/L                     1.00 (0.80--1.28)              1.04 (0.84--1.34)           0.634
   LDL, mmol/L                     2.31 (1.81--2.85)              2.24 (1.64--2.95)           0.334
   CK, U/L                       82.50 (41.85--165.25)          77.60 (39.95--153.40)         0.183
   c-TnT, ng/L                     0.05 (0.02--0.21)              0.05 (0.02--0.19)           0.846
   NT-pro BNP, pg/mL          6947.37 (3585.08--19535.10)    5537.39 (2740.15--16904.50)      0.147
   Hemoglobin, g/L              120.00 (99.00--146.00)          126.00 (83.00--137.00)        0.751
   RBC, 10^12^/L                   4.00 (3.39--4.45)              4.05 (3.36--4.68)           0.647
   WBC, 10^9^/L                   7.27 (5.95--10.28)              7.76 (5.91--9.20)           0.560
   PLT, 10^9^/L                 186.50 (135.25--238.00)        187.00 (137.50--248.00)        0.110
  ABG                                                                                      
   pH value                        7.36 (7.36--7.43)              7.39 (7.38--7.44)           0.844
   PaO~2~, mmHg                  76.00 (61.40--93.40)            80.21 (61.60--94.28)         0.264
   PaCO~2~, mmHg                 35.00 (30.80--40.50)            37.72 (32.03--40.48)         0.273
   HCO~3~, mmHg                  21.96 (18.50--24.10)            22.50 (19.80--24.90)         0.258
   SaO~2~, %                     92.50 (91.10--97.90)            92.70 (92.50--97.40)         0.748
  Echocardiographic                                                                        
   LVDD, mm                      54.00 (45.00--57.00)            51.00 (45.00--58.00)         0.601
   LVSD, mm                      38.00 (31.00--45.00)            38.00 (32.00--47.00)         0.181
   LVEF, %                       43.00 (35.00--49.00)            44.00 (35.00--52.00)         0.432
   FS, %                         22.00 (18.00--29.00)            23.00 (20.00--30.00)         0.846

Data were presented as mean ± SD, *n* (%) or median (25th--75th percentiles). ALT: alanine transferase; AST: aspartate aminotransferase; ABG: arterial blood gas; BUN: blood urea nitrogen; BMI: body mass index; CK: creatine kinase; c-TnT: cardiac troponin T; Cr: creatinine; DBP: diastolic blood pressure; FS: fractional shortening; HR: heart rate; HDL: high density lipoprotein; LDL: low density lipoprotein; LVDD: left ventricular diastolic diameter; LVSD: left ventricular systolic dysfunction; LVEF: left ventricular ejection fraction; NT-pro BNP: N-terminal pro-b-type natriuretic peptide; PLT: platelets; PH: potential of hydrogen; PaO~2~: partial pressure of O~2~; PaCO~2~: partial pressure of CO~2~; RR: respiratory rate; RBC: red blood count; SBP: systolic blood pressure; triglyceride; T-CH: total cholesterol; WBC: white blood count; γ-GT: γ-glutamyl transpeptidase.

![ROC curve of RPSS for validation group.\
ROC: receiver operating characteristic; RPSS: risk prediction score system.](jgc-14-11-669-g006){#jgc-14-11-669-g006}

4. Discussion {#s4}
=============

HF is one of the most burgeoning healthcare problems in the cardiology department. Early prediction and identification of the onset of worsening conditions in high-risk heart failure patients is urgent and necessary for clinical management. Although numerous studies have shown that HF mortality has steadily declined in America recently,[@b12]--[@b14] HF mortality in China remains at a higher level and has an upward trend. This difference is caused by a variety of reasons, such as medical conditions, social conditions, among others. Several studies have shown that a number of risk factors are related to short-term and long-term mortality after discharge, including age, gender,[@b15] ventricular function,[@b16],[@b17] management,[@b18] and so on.[@b19] Despite research revealing risk factors for HF mortality, data on HF mortality prediction in elderly patients during admission are limited. The response of several markers such as renal function and natriuretic peptide levels, has consistently failed to predict improvement in outcomes with investigational therapies.[@b20],[@b21] Although many established algorithms are currently available, these studies have not been validated in Chinese populations. Additionally, arterial blood gas analysis is an important measure for clinical management; however, large sample studies did not include arterial blood gas analysis indicators as candidate factors.[@b3],[@b9],[@b22],[@b23] Therefore, we combined clinically common factors and an arterial blood gas index to establish another score system that may be more suitable for Chinese patients. Our study showed that the RPSS model had good discriminative capability for in-hospital mortality. In our study, it is shown that several commonly used cardiovascular and non-cardiovascular risk factors may cause rapid development or deterioration of signs and symptoms of heart failure during hospitalization.

Our study showed that the lowest pH quartile was associated with an increased possibility of adverse cardiac events. In HF patients with cardiogenic pulmonary edema, cardiac congestion leads to pulmonary edema with impaired gas exchange and ow cardiac output with a decreased tissue perfusion leads to metabolic acidosis. Lactate is a normal by-product of glucose and amino acid metabolism. Lactic acidosis will be buffered by serum bicarbonate, resulting in metabolic acidosis that is expressed by a low bicarbonate level and low pH value. The poorer the tissue perfusion, the more lactic acid will be produced and the lower the pH value.[@b24] Thus, the pH value can be used as a comprehensive marker for backward and forward failure, and acid--base balance can be used to assess the general status of heart function in HF patients.[@b25]

In addition, the left ventricular end diameter and ejection fraction are two commonly used echocardiographic parameters that can provide cardiac function information. Our study showed that the incidence of adverse events during admission in patients with reduced LVEF was higher than that in patients with preserved LVEF. However, another study showed that the outcomes during hospitalization between reduced LVEF patients and preserved LVEF patients were similar.[@b26] Previous reports have suggested that an ischemic cause is associated with an increased risk of mortality in patients with reduced LVEF, but not in those with preserved LVEF.[@b27],[@b28] This is mainly caused by the different characteristics of hospitalized patients.

Furthermore, renal dysfunction plays an important role in the progression of HF. Renal dysfunction may aggravate or trigger an episode of HF, as well as contribute to the further progression of HF and poor outcomes.[@b29]--[@b31] Renal dysfunction includes a decreased glomerular ﬁltration rate \[assessed using different glomerular ﬁltration rate (GFR) formulas based on the measurement of circulating creatinine and cystatin C\], abnormal tubular function \[as reﬂected by high levels of neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule1 (KIM1) in both peripheral blood and urine\] and inadequate endocrine activity \[as reflected by inadequate secretion of erythropoietin (EPO)\].[@b32] It is suggested that renal-dysfunction may be the result of generalized neurohormonal activation, inﬂammation, oxidative stress, impaired intra-renal hemodynamics as a consequence of either abnormal extra-renal hemodynamics affecting renal blood ﬂow and pressures or deranged intra-renal hemodynamic regulatory mechanisms, intrinsic renal disease (e.g., diabetes, hypertension), and iatrogenic causes (e.g. high-dose loop diuretic therapy).[@b30],[@b33],[@b34] creatinine (Cr) and BUN are the most commonly used markers of renal function in the clinical setting. They are not only markers of renal dysfunction and hypoperfusion but may also reﬂect neurohormonal activation in HF.[@b35] In our study, the areas under the Cr, BUN and eGFR curves were 0.779, 0.757 and 0.773, respectively. These results prove that renal function is related to adverse cardiac events in HF patients. This is consistent with the findings of two famous registries that demonstrated that renal function at admission is among the best discriminators between hospital survivors and non-survivors.[@b3],[@b23]

Our ﬁndings demonstrated that HR; LVEF, as determined from echocardiography; pH value; eGFR; and NT-pro BNP should be considered when assessing the risk of in-hospital mortality after admission for patients with AHF. Our risk prediction model, RPSS, has important significance for precision risk stratification of in-hospital patients with AHF and could provide better prediction for in-hospital mortality.

These ﬁndings should be considered in the context of several limitations. This study is a single-center, retrospective control study and the population was rather small. Therefore, cross-validation or bootstrap resampling would be a better procedure for grouping and analysis. Large sample size studies in the future could adopt these methods. Additionally, this model reports in-hospital mortality only and was not validated for post-discharge outcomes. Other factors might be of prognostic value for post-discharge mortality or re-hospitalization. The mortality risk factors might have been inﬂuenced by other factors that were included in the database or that were considered to be candidate variables. Thus, linear terms might be not appropriate for predictors with non-linear associations; restricted cubic splines or fractional polynomials might be better choices.
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